Compass Wealth Management LLC Sells 52 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Compass Wealth Management LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,234 shares of the medical research company’s stock after selling 52 shares during the quarter. Compass Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $763,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Brookstone Capital Management grew its position in shares of Thermo Fisher Scientific by 252.4% during the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after purchasing an additional 3,142 shares in the last quarter. BDF Gestion bought a new position in Thermo Fisher Scientific in the 2nd quarter worth about $6,368,000. Aviance Capital Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 20.9% in the 1st quarter. Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock valued at $7,581,000 after acquiring an additional 2,251 shares in the last quarter. Lord Abbett & CO. LLC grew its holdings in shares of Thermo Fisher Scientific by 1.9% during the first quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock worth $45,478,000 after purchasing an additional 1,480 shares in the last quarter. Finally, Advisors Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 5.8% in the first quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock worth $64,613,000 after purchasing an additional 6,089 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on TMO shares. TD Cowen boosted their price target on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Wells Fargo & Company began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 target price for the company. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Royal Bank of Canada reissued an “outperform” rating and set a $767.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 20th. Finally, Stephens started coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $656.16.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $599.25 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $627.88. The stock has a market cap of $228.91 billion, a P/E ratio of 37.17, a price-to-earnings-growth ratio of 3.86 and a beta of 0.77. The firm’s fifty day simple moving average is $607.88 and its 200 day simple moving average is $583.92.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the prior year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific’s revenue was down 1.4% on a year-over-year basis. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,084 shares of company stock worth $14,094,292. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.